Comorbidity and survival among women with ovarian cancer: evidence from prospective studies

Abstract

The relationship between comorbidity and ovarian cancer survival has been controversial so far. Therefore, we conducted a meta-analysis to summarize the existing evidence from prospective studies on this issue. Relevant studies were identified by searching the PubMed, EMBASE, and ISI Web of Science databases through the end of January 2015. Two authors independently performed the eligibility evaluation and data abstraction. Random-effects models were used to estimate summary hazard ratios (HRs) and 95% confidence intervals (CIs) for overall survival. Eight prospective studies involving 12,681 ovarian cancer cases were included in the present study. The summarized HR for presence versus absence of comorbidity was 1.20 (95% CI = 1.11–1.30, n = 8), with moderate heterogeneity (I2 = 31.2%, P = 0.179). In addition, the summarized HR for the highest compared with the lowest category of the Charlson’s comorbidity index was 1.68 (95% CI = 1.50–1.87, n = 2), without heterogeneity (I2 = 0%, P = 0.476). Notably, a significant negative impact of comorbidity on ovarian cancer survival was observed in most subgroup analyses stratified by the study characteristics and whether there was adjustment for potential confounders. In conclusion, the findings of this meta-analysis suggest that underlying comorbidity is consistently associated with decreased survival in patients with ovarian cancer. Comorbidity should be taken into account when managing these patients.

Fluoxetine and congenital malformations: a systematic review and meta‐analysis of cohort studies

“…If the selected study did not include a risk estimate, we calculated the unadjusted RR and the 95% CI from the raw data for simplicity [16,17,23,24,[48][49][50][51]. Estimates were pooled using a random-effects model to calculate the summarized RRs and 95% CI [52][53][54]. If the selected studies reported the results of cardiovascular malformations as other outcomes but with similar definitions [e.g., congenital heart defect (CHD) or cardiac malformations], we combined the risk estimate to calculate the summarized RR of cardiovascular malformation.…”

Sertraline use in the first trimester and risk of congenital anomalies: a systemic review and meta‐analysis of cohort studies

“…Random‐effects models by DerSimonian and Laird were applied to obtain summarized OR estimates across the included studies. We calculated the I 2 statistic to quantify the magnitude between‐study heterogeneity, and assigned values of 50% or less, 51%–75%, and 76% or more for low‐, moderate‐ and high‐ heterogeneity, respectively . Subgroup analysis was carried out based on geographic location (Europe, North America and other regions).…”

Association between patients' perception of the comorbidity burden and symptoms in outpatients with common solid tumors

“…Cancer patients with comorbidities have poorer survival and often do not receive various standard cancer and supportive-care therapies. [9][10][11] The impact of cancer and preexisting comorbidities on patients' symptom burden is only beginning to be appreciated. Although a few studies have highlighted the impact of multimorbidity on the receipt of cancer treatment, 12 fatigue and pain symptoms, 13 and mortality, 14 data on how comorbidity influences a patient's illness experience and overall symptom burden are sparse.…”